Moderna (MRNA) EBT (2017 - 2026)

Moderna (MRNA) has reported EBT for 10 consecutive years, with -$767.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT rose 6.23% year-over-year to -$767.0 million in Q2 2026; TTM through Jun 2026 was -$3.1 billion, a 4.82% decrease from a year earlier, with the FY2025 full-year figure at -$2.8 billion, up 23.26% from the prior year.
• EBT was -$767.0 million for Q2 2026 at Moderna, up from -$1.3 billion in the prior quarter.
• Over five years, EBT peaked at $4.2 billion in Q1 2022 and troughed at -$2.0 billion in Q3 2023.
• A 5-year average of -$157.9 million and a median of -$783.0 million in 2025 frame the typical range for EBT.
• Across the five-year window, EBT surged 235.63% in 2022 and plunged 1791.43% in 2024, its largest moves.
• Over 5 years, EBT stood at $1.7 billion in 2022, then sank by 95.77% to $70.0 million in 2023, then sank by 1791.43% to -$1.2 billion in 2024, then surged by 32.52% to -$799.0 million in 2025, then gained by 4.01% to -$767.0 million in 2026.
• The last three EBT figures came in at -$767.0 million (Q2 2026), -$1.3 billion (Q1 2026), and -$799.0 million (Q4 2025), per Business Quant data.